Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TLR3 | O15455 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.39 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.39 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15021653 | 1.00 | MEN1 (0.43) | MEN1KMT2ATLR3MAOAMAOB | |
| SCHEMBL31253977 | 1.00 | MEN1 (0.43) | MEN1KMT2ATLR3MAOAMAOB | |
| SCHEMBL13573386 | 1.00 | MEN1 (0.43) | MEN1KMT2ATLR3MAOAMAOB | |
| Alcohol SCHEMBL10531474 | 0.93 | KCNE1 (0.42) | MEN1KMT2ATLR3MAOAMAOB | |
| SCHEMBL5733934 | 0.82 | KCNE1 (0.38) | MAOAMAOBKCNE1KCNQ1HTT | |
| SCHEMBL24043239 | 0.81 | HTT (0.39) | MAOAMAOBTRPV1KCNE1KCNQ1 | |
| SCHEMBL23746634 | 0.79 | ALDH1A1 (0.42) | KMT2ATRPV1HTTLMNA | |
| SCHEMBL24075724 | 0.79 | ALDH1A1 (0.42) | KMT2ATRPV1HTTLMNA | |
| SCHEMBL13257631 | 0.79 | ALDH1A1 (0.42) | KMT2ATRPV1HTTLMNA | |
| SCHEMBL24090500 | 0.79 | KMT2A (0.36) | KMT2ATRPV1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119923278-A | Dendrimer compositions for targeted delivery of fantasy therapeutic agents | 约翰霍普金斯大学 | 2025-05-02 | — | — | CN | disclosed |
| CN-117642383-A | Crystalline salts of dimethyl-4-hydroxytryptamine | 卡纳-化学有限责任公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-114262250-A | Synthetic method of aromatic ring benzyl ortho-position dialkyl | 乐威医药（江苏）股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2020223536-A1 | SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2020-11-05 | — | — | WO | disclosed |
| WO-2015142903-A2 | METHOD OF CONTROLLING LACTATE PRODUCTION WITH PIPERDINE-DIONE DERIVATIVES | GENENTECH, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015140133-A1 | PIPERIDINE-DIONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-24 | — | — | WO | disclosed |
| US-8859584-B2 | TRPV1 antagonists | ABBVIE, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| CN-103342700-A | 11[beta]-hydroxysteroid dehydrogenase type 1 inhibitor | TONGHUA JIDA PHARMACEUTICAL CO LTD | 2013-10-09 | — | — | CN | disclosed |
| US-20130158067-A1 | TRPV1 Antagonists | ABBVIE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-7662811-B2 | N-(((5R)-5-((1-methylethyl)amino)-5,6,7,8-tetrahydro-2-naphthalenyl)methyl)-2-((2R)-1-((4-methylphenyl)sulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-pyrazinyl)acetamide; for treatment of pain and diseases, such as inflammation mediated diseases | AMGEN INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-7414068-B2 | Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them | DONGBU HANNONG CHEMICAL CO., LTD. (KR) | 2008-08-19 | — | — | US | disclosed |
| WO-2008007210-A2 | NITROGENOUS N-SUBSTITUTED 4-SPIRO-HETEROCYCLIC 2, 2 -DIMETHYLCHROMANE DERIVATIVES | UNIVERSITA' DI PISA (IT) | 2008-01-17 | — | — | WO | disclosed |
| EP-1817294-A1 | 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS | Amgen Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006019975-A1 | 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS | AMGEN INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060025400-A1 | 1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use | AMGEN INC. | 2006-02-02 | — | — | US | disclosed |
| WO-1996026934-A1 | SYNTHESIS OF OPTICALLY ACTIVE CALANOLIDES A AND B AND ENANTIOMERS AND RELATED COMPOUNDS | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 1996-09-06 | — | — | WO | disclosed |
| EP-0446235-A1 | PROCESS FOR THE PRODUCTION AND APPLICATION OF FUSION-ADHESIVE AND/OR SEALING COMPOUNDS WHICH CROSS-LINK UNDER THE ACTION OF HUMIDITY | Henkel Kommanditgesellschaft auf Aktien (DE) | 1991-09-18 | — | — | EP | disclosed |
| US-5043344-A | Unsaturated N-benzopyranyllactams | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-08-27 | — | — | US | disclosed |
| WO-1990006332-A1 | PROCESS FOR THE PRODUCTION AND APPLICATION OF FUSION-ADHESIVE AND/OR SEALING COMPOUNDS WHICH CROSS-LINK UNDER THE ACTION OF HUMIDITY | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1990-06-14 | — | — | WO | disclosed |
| EP-0337179-A1 | Unsaturated N-benzopyranyllactams | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025400-A1 | 1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use | AADAC, PTGES2, LTC4S | MEN1 4335/4885KMT2A 1654/4885TLR3 457/4885 |
| US-20130158067-A1 | TRPV1 Antagonists | TRPV1, NPY1R, MRGPRX1 | MEN1 3289/4885KMT2A 3154/4885TLR3 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.